Annual influenza vaccination is recommended for all persons ≥6 months old without a contraindication.1-6 Influenza vaccines available this season in the US are listed in Table 3.
COMPOSITION — All influenza vaccines available in the US this season are trivalent: they contain two influenza A virus antigens and one influenza B virus antigen (see Table 1). Influenza A viruses are the primary cause of influenza-related morbidity and mortality, especially in older adults. Illness caused by...
ISSUE
The injectable GIP/GLP-1 receptor agonist tirzepatide (Mounjaro – Lilly), which was approved by the FDA in 2022 for treatment of type 2 diabetes,1 has now been approved to reduce the risk of MACE in adults with type 2 diabetes who are at high risk for these events. Tirzepatide is also available as Zepbound for chronic weight management and for treatment of obstructive sleep apnea in adults with obesity.2,3
GLP-1 RECEPTOR AGONISTS — The injectable GLP-1 receptor agonists semaglutide (Ozempic), dulaglutide (Trulicity), and liraglutide (Victoza) and oral semaglutide (Ozempic, Rybelsus) are also approved for cardiovascular risk reduction in patients with type 2 diabetes. These drugs have reduced the risk of MACE by up to 20% in clinical trials in patients with type 2 diabetes.4
A CLINICAL STUDY — FDA approval of tirzepatide for …